CLINICAL STUDY

Wnt receptors, bone mass, and fractures: gene-wide association analysis of *LRP5* and *LRP6* polymorphisms with replication

José A Riancho, José M Olmos, Begoña Pineda¹, Carmen García-Ibarbia, María I Pérez-Núñez², Daniel N Nan, Javier Velasco, Antonio Cano³, Miguel A García-Pérez¹, María T Zarrabeitia⁴ and Jesús González-Macías

Department of Internal Medicine, Hospital U.M. Valdecilla-IFIMAV, University of Cantabria, RETICEF, Avda Valdecilla s/n, 39008 Santander, Spain,

¹Research Foundation, Hospital Clínico Universitario, Av. Blasco Ibañez, 17, E 46010 Valencia, Spain, ²Service of Orthopedic Surgery and Traumatology, Hospital U.M. Valdecilla-IFIMAV, University of Cantabria, 39008 Santander, Spain, ³Department of Pediatrics, Obstetrics, and Gynecology, University of Valencia, and University Hospital Dr. Peset University Hospital, Avda Gaspar Aguilar 90, 4017 Valencia, Spain and ⁴Unit of Legal Medicine, University of Cantabria, C/Herrera Oria s/n 39011 Santander, Spain

(Correspondence should be addressed to J A Riancho; Email: rianchoj@unican.es)

Abstract

Objective: Genes explaining the susceptibility to osteoporosis have not been fully elucidated. Our objective was to explore the association of polymorphisms capturing common variations of the lipoprotein receptor-related protein (*LRP*) 5 and 6 genes, encoding two Wnt receptors, with femoral neck bone mineral density (BMD) and osteoporotic fractures of the spine and the hip.

Design: Cross-sectional, case–control, and replication genetic association study.

Methods: Thirty-nine tagging and functional single nucleotide polymorphisms (SNPs) were analyzed in a group of 1043 postmenopausal women and 394 women with hip fractures. The results were replicated in a different group of 342 women.

Results: Three SNPs of the *LRP6* gene were associated with BMD (nominal uncorrected *P* values <0.05) in the discovery cohort. One showed a significant association after multiple test correction; two of them were also associated in the replication cohort, with a combined standardized mean difference of 0.51 (*P*=0.009) and 0.47 (*P*<0.003) across rs11054704 and rs2302685 genotypes. In the discovery cohort, several *LRP5* SNPs were associated with vertebral fractures (odds ratio (OR) 0.67; *P*=0.01), with hip fractures (unadjusted ORs between 0.59 and 1.21; *P*=0.005–0.033, but not significant after multiple test adjustment or age adjustment), and with height and the projected femoral neck area, but not with BMD. Transcripts of *LRP5* and *LRP6* were similarly abundant in bone samples.

Conclusions: In this study, we found common polymorphisms of *LRP5* associated with osteoporotic fractures, and polymorphisms of the *LRP6* gene associated with BMD, thus suggesting them as likely candidates to contribute to the explanation of the hereditary influence on osteoporosis.

European Journal of Endocrinology 164 123–131

Introduction

The Wnt family includes more than 15 proteins that have been shown to play an important role in organ development and the homeostasis of several adult tissues, including bone. Wnt ligands stimulate the differentiation of pluripotential precursors toward the osteoblastic lineage, and have an anabolic effect on bone. Intracellular signals transducing Wnt effects are complex and include several pathways; the best known among them is the so-called canonical pathway. It starts with the union of Wnt ligands to a membrane receptor complex constituted by a lipoprotein receptor-related peptide (LRP) and a frizzled protein. There are at least ten members of the frizzled family. There are also several LRPs, with positive or negative effects on Wnt signaling (1). The best-known members of the LRP family are *LRP5* and *LRP6*. The role of *LRP5* was emphasized by

the discovery of some patients with either high or low bone mass phenotypes, caused by activating and loss-of-function mutations respectively of *LRP5*. Furthermore, several candidate gene studies and some multicenter large-scale and genome-wide association studies (GWASs) suggested that common *LRP5* polymorphisms might influence bone mineral density (BMD) in the general population. Nevertheless, recent animal studies have raised some doubts about the direct role of *LRP5* in bone (2). The role of *LRP6* has not been studied extensively, but both *LRP5* and *LRP6* appear to be necessary for skeletal homeostasis (3, 4). Moreover, some investigators suggested that *LRP6* polymorphisms influence BMD (5, 6), but the results were not confirmed in other studies (7, 8). Therefore, this is a controversial issue. Population differences and the particular polymorphisms included in those analyses may explain the discordant results. On the other hand, little is known

about the relationship between *LRP5/6* polymorphisms and hip fractures, which are the most devastating osteoporotic fractures. Therefore, the aim of this study was to use a gene-wide approach to explore the association of common polymorphisms of *LRP5* and *LRP6* genes with femoral neck BMD and osteoporotic fractures of the spine and the hip.

Materials and methods

Subjects

To study the association of genetic polymorphisms with BMD and vertebral fractures we performed a cross-sectional study that included 1043 postmenopausal women over 50 years of age (age 51–90) living in Cantabria, a region in northern Spain with a population of 550 000. They included volunteers recruited by advertisements and women sent to our clinic because of osteoporosis concerns (Santander group) and women

taking part in a population-based cohort study on the epidemiology of osteoporosis (Camargo cohort) (9). Both groups belonged to the same geographical region. Femoral neck BMD was measured by DXA using a Hologic QDR 4500 densitometer. The projected neck area in the DXA output was also analyzed. Since the densitometer uses a fixed length for femoral neck assessment, the projected area is a function of the neck diameter. The presence of vertebral fractures was defined as a loss of vertebral body height higher than 20% in lateral X-rays (available in 637 women), which were assessed by an experienced reader, prior to genotyping.

To study the association with hip fractures, we recruited a convenience sample of unselected patients admitted to a hospital because of a hip fracture, 60–90 years of age ($n=394$). Those with fractures due to high-impact trauma (such as traffic accidents and falls from a height) were excluded. Control subjects ($n=529$) included women from the Santander and Camargo

Table 1 Polymorphisms genotyped.

Gene	Chrom	SNP	Position	Minor allele	Major allele	MAF	P (HWE)
<i>LRP5</i>	11	rs4988330	67837575	T	C	0.08	0.43
<i>LRP5</i>	11	rs7116604	67841050	A	G	0.13	0.83
<i>LRP5</i>	11	rs312014	67841538	C	G	0.39	0.35
<i>LRP5</i>	11	rs4988331	67841909	T	C	0.08	0.65
<i>LRP5</i>	11	rs4988300	67845407	G	T	0.48	0.81
<i>LRP5</i>	11	rs3781600	67849913	C	G	0.11	0.20
<i>LRP5</i>	11	rs312024	67851007	A	G	0.31	0.62
<i>LRP5</i>	11	rs314779	67854402	G	T	0.31	0.35
<i>LRP5</i>	11	rs606989	67858576	T	C	0.09	0.06
<i>LRP5</i>	11	rs314756	67868248	G	A	0.07	1
<i>LRP5</i>	11	rs3781596	67870578	C	G	0.14	0.69
<i>LRP5</i>	11	rs643981	67872340	T	C	0.44	0.88
<i>LRP5</i>	11	rs312786	67876553	T	G	0.29	0.64
<i>LRP5</i>	11	rs312788	67878871	G	T	0.44	0.85
<i>LRP5</i>	11	rs160607	67886182	A	G	0.43	0.73
<i>LRP5</i>	11	rs11826287	67903237	C	T	0.19	0.26
<i>LRP5</i>	11	rs671191	67906557	C	T	0.38	0.02
<i>LRP5</i>	11	rs4930573	67920032	G	C	0.32	0.87
<i>LRP5</i>	11	rs587397	67923999	G	C	0.09	0.65
<i>LRP5</i>	11	rs4988321	67930765	A	G	0.08	1
<i>LRP5</i>	11	rs2306862	67934086	T	C	0.20	0.55
<i>LRP5</i>	11	rs923346	67938951	C	T	0.20	0.60
<i>LRP5</i>	11	rs1784235	67942076	C	T	0.28	0.76
<i>LRP5</i>	11	rs556442	67949266	G	A	0.39	0.47
<i>LRP5</i>	11	rs12417014	67957583	T	C	0.10	0.13
<i>LRP5</i>	11	rs3781579	67966294	G	A	0.16	0.09
<i>LRP5</i>	11	rs632605	67972530	A	G	0.07	1
<i>LRP6</i>	12	rs2075241	12182746	C	G	0.14	0.05
<i>LRP6</i>	12	rs718403	12188223	T	C	0.24	0.43
<i>LRP6</i>	12	rs11054704	12191036	A	G	0.13	0.45
<i>LRP6</i>	12	rs2302685	12193165	C	T	0.16	0.53
<i>LRP6</i>	12	rs12833575	12216108	G	A	0.06	0.68
<i>LRP6</i>	12	rs2417085	12222642	C	T	0.47	0.42
<i>LRP6</i>	12	rs10845493	12223463	T	C	0.15	0.52
<i>LRP6</i>	12	rs10082834	12225273	C	G	0.11	0.48
<i>LRP6</i>	12	rs17374170	12255678	C	T	0.08	1
<i>LRP6</i>	12	rs17302049	12256592	G	A	0.17	0.81
<i>LRP6</i>	12	rs1181334	12258855	T	G	0.18	1

groups within the same age range, but without osteoporotic fractures.

Women with present or past diseases (cancer, rheumatoid arthritis, malabsorption, severe systemic diseases, etc.) or treatments (corticosteroids, anticonvulsants, hormone replacement therapy, etc.), known to affect bone metabolism, or with non-Spanish ancestors were excluded. The study protocol was approved by the institutional committee of ethics in clinical research, and informed consent was obtained from the subjects or their representatives.

The results about genetic polymorphisms and BMD were replicated in a cohort of women attending a menopause clinic in Valencia, a region in eastern Spain. After applying similar exclusion criteria, the cohort included 342 Caucasian postmenopausal women aged 41–69 years. BMD was measured by DXA using either a Lunar or a Norland densitometer. The results from different densitometers were standardized as proposed by Lu *et al.* (10).

Genotyping

The Hapmap database was explored to identify single nucleotide polymorphisms (SNPs) of the *LRP5* and *LRP6* genes in the Caucasian population. Then, tag-SNPs were selected using the algorithms available in Haploview with the 'aggressive tagging' option (11). Minor allele frequency (MAF) of 0.1 and r^2 0.8 were used as criteria. In addition, we included some SNPs with potential regulatory function as assessed by the bioinformatics suite Pupa (12, 13). Therefore, 31 SNPs of the *LRP5* gene and 11 of the *LRP6* gene were finally selected. DNA was isolated from peripheral blood or buccal swabs by using column-based commercial methods and quantified with the Qubit procedure (Invitrogen). Then alleles at each locus were analyzed by a mass-array Sequenom platform at the Centro Nacional de Genotipado (Santiago de Compostela, Spain). In a subsample of study participants, the rs3736228 polymorphism of the *LRP5* gene was

analyzed by using a Taqman assay (Applied Biosystems, Foster City, CA, USA). Polymorphisms associated with BMD in the discovery cohort were analyzed in the replication cohort by using the same procedure (mass-array) for genotyping at Unidad Central de Investigación (Facultad de Medicina, Valencia, Spain). Replicate samples were included to confirm the consistency of results.

Gene expression

Trabecular bone samples were obtained from the femoral heads of patients subjected to hip replacement because of severe osteoarthritis. RNA was isolated with Trizol (Invitrogen) and further purified by using a column adsorption procedure (Qiagen). Aliquots of RNA (250 ng) were reverse transcribed with the Superscript III kit (Invitrogen) and quantified by real-time PCR in an ABI7300 apparatus (Applied Biosystems), using specific primers and FAM-labeled probes for *LRP5* and *LRP6* (Taqman gene expression assays, Applied Biosystems). The results were then normalized to the expression of the housekeeping gene TATA box protein (*TBP*) and an universal reference RNA (Stratagene), by the $2^{-\Delta\Delta C_t}$ method (14).

Statistical analysis

Haplotypic blocks were estimated by the Gabriel method and implemented in Haploview (11). The departure from the Hardy–Weinberg equilibrium was tested with PLINK software (15). The association of alleles with BMD was studied at the single-locus level, assuming additive and recessive models, with PLINK. The presence of population stratification was explored with STRUCTURE software, running a dataset with five markers located in different chromosomes (16). BMD results in different cohorts were combined by computing the Hedges' standardized weighted mean difference with MIX software (17, 18). The significance threshold after multiple test correction for each gene was estimated by

Table 2 Characteristics of study subjects (mean $\pm$ s.d. or percentages).

Cohort/phenotype	Santander/BMD–vertebral fractures ($n=608$)	Camargo/BMD–vertebral fractures ($n=435$)	Hip fractures ($n=394$)	Valencia/BMD ($n=342$)
Age (years)	69 $\pm$ 7	64 $\pm$ 9	80 $\pm$ 7	52 $\pm$ 5
Weight (kg)	66 $\pm$ 10	70 $\pm$ 12	–	66 $\pm$ 10
Height (cm)	155 $\pm$ 6	155 $\pm$ 6	–	158 $\pm$ 6
BMI (kg/m ²)	27.6 $\pm$ 4.1	28.9 $\pm$ 4.8	–	26.5 $\pm$ 4.3
Age at menopause (years)	50 $\pm$ 5	49 $\pm$ 5	–	48 $\pm$ 4
Vertebral fractures ^a (%)	36	8	–	–
Arm/forearm fractures (%)	11	8.4	16	9
BMD ^b (g/cm ²)	0.671 $\pm$ 0.112	0.720 $\pm$ 0.117	–	0.804 $\pm$ 0.115
Smoking (%)	4	12	3	26
Calcium intake ^c (mg/day)	659 $\pm$ 397	680 $\pm$ 358	620 $\pm$ 376	–

^aData from 637 women with X-rays.

^bHologic DXA in Cantabria and standardized (Lunar or Norland) in Valencia.

^cFrom dairy products.

Figure 1 Association of *LRP5* polymorphisms with femoral neck BMD. Nominal *P* values under an age-adjusted recessive model.

considering the effective number of independent marker loci, using the single nucleotide spectral decomposition software (SNPSpD), developed by Nyholt (19). Uncorrected nominal *P* values are shown, unless otherwise indicated. *P* values <0.05 were considered as statistically significant. The study power (estimated with QUANTO software, available at <http://hydra.usc.edu/gxe/>) was higher than 89% to find genetic effects explaining at least 1% of BMD variance. Power to detect a fracture odds ratio (OR) of 1.4 or higher was 80 and 54%, for hip fractures and vertebral fractures respectively, assuming an additive model and an MAF of 0.2.

Results

Bone mineral density

Four SNPs of the *LRP5* gene were excluded due to inaccurate separation or low calling rate. The genotyping rate in the remaining set (Table 1) was 97.4%. The allelic frequencies were similar to those reported in other Caucasian populations and there was no evidence for departure from the Hardy–Weinberg equilibrium. Only one SNP was associated with a nominal *P* value <0.05 (0.02, well above the significance of 0.003 threshold after multiple test correction) (Table 1). No significant hidden population stratification was detected while running the STRUCTURE software. The characteristics of women included in the study are shown in Table 2.

The rs4988321 polymorphism of the *LRP5* gene showed a marginal association with age-adjusted BMD ($P=0.0488$; Fig. 1), which did not reach the multiple-test-adjusted threshold of significance (estimated as $P=0.003$). Three SNPs of the *LRP6* gene were also associated with BMD: rs11054704 (additive $P=0.035$; recessive $P=0.016$), rs2302685 (additive $P=0.058$; recessive $P=0.0039$), and rs10845493 (additive $P=0.054$; recessive $P=0.036$; Fig. 2). Only the *P* value for the rs2302685 polymorphism was below

the multiple-test-adjusted threshold of significance (estimated as 0.006 for the *LRP6* SNP set).

We selected those three SNPs for replication in a different cohort (Valencia). In this cohort, rs10845493 was not associated with BMD, but the association was replicated for rs11054704 ($P=0.016$, additive model) and almost reached statistical significance for rs2302685 ($P=0.057$, additive model). The combined standardized weighted mean differences between women with opposite genotypes were 0.51 s.d. (95% confidence interval 0.13–0.89) and 0.47 s.d. (95% confidence interval 0.16–0.77) for rs11054704 and rs2302685 loci respectively (Table 3).

Fractures

The association of genetic polymorphisms with fractures was analyzed in 637 women with spine X-rays available (140 with osteoporotic vertebral fractures and 497 controls without fractures). Several polymorphisms of the *LRP5* gene tended to be associated with fractures, with nominal *P* values <0.05, but they did not reach the multiple test threshold for significance (0.003). Loci rs312788 and rs160607 showed the most significant association. The age-adjusted OR was 0.67 in both the cases ($P=0.009$ and 0.01 respectively; Fig. 3). The rs3736228 polymorphism could not be included in the multiplex reaction along with other polymorphisms and was genotyped later in a single assay. It also tended to be associated with fractures in our population (OR 1.5; 95% confidence interval 1.1–2.2; $P=0.025$).

Since *LRP5* polymorphisms showed a trend for association with vertebral fractures, but not with BMD, we explored their relationship with body size. After excluding women with vertebral fractures

Figure 2 Association of *LRP6* polymorphisms with femoral neck BMD. Nominal *P* values under an age-adjusted recessive model. Full colour version of this figure available via <http://dx.doi.org/10.1530/EJE-10-0582>.

Table 3 Association of *LRP6* genotypes with BMD in the discovery and replication cohorts and combined estimate of effect. *P* values for age-adjusted additive models in each cohort and standardized weighted mean difference (SWMD) between opposite homozygotes (in s.d. units).

Locus	Cohort			SWMD
	Cantabria	Valencia	Combined	
rs11054704				
AA	0.626±0.180 (19)	0.757±0.103 (8)		
AG	0.681±0.101 (201)	0.782±0.108 (90)		
GG	0.688±0.117 (782)	0.813±0.116 (222)		
<i>P</i> value	0.035	0.016	0.009	0.51 (GG–AA)
rs2302685				
CC	0.626±0.154 (30)	0.770±0.090 (13)		
CT	0.687±0.104 (254)	0.788±0.112 (91)		
TT	0.687±0.117 (724)	0.812±0.119 (187)		
<i>P</i> value	0.058	0.057	<0.003	0.47 (TT–CC)

(which can cause a loss of height by themselves), several *LRP5* polymorphisms were associated with height (uncorrected *P* values 0.002–0.04; Fig. 3). Likewise, they were associated with the projected femoral neck area, as measured from the densitometer output, even after controlling for height (*P* values=0.0014–0.048; Fig. 3).

Several *LRP5* polymorphisms also tended to be associated with hip fractures (uncorrected *P* values <0.05), including some found associated with vertebral fractures (rs4988300 and rs160607). However, the hip fracture group was somewhat older than the control group. After adjusting the results, introducing age as a covariate, similar ORs were observed, but with larger confidence intervals and were no longer statistically significant (Table 4).

SNPs of the *LRP6* gene were not significantly associated with either vertebral or hip fractures.

The incomplete assessment of fractures in the Valencia cohort did not allow replicating fracture association data.

Gene expression

Gene transcripts were measured in 17 femoral bone samples of patients with osteoarthritis undergoing hip replacement surgery. Transcripts of *LRP5* and *LRP6* were similarly abundant: 1.5 (range 0.1–4.9) and 1.2 (range 0.1–5.7) arbitrary units respectively (not significantly different).

Discussion

Rare cases of loss-of-function or gain-of-function mutations of *LRP5* are associated with marked decreases or increases respectively of bone mass (20–23). Although the skeletal impact of common allelic variants is less clear, several polymorphisms of the *LRP5* gene have been associated with bone mass and fractures, in candidate gene studies (6, 24, 25) and in some, but not all, GWASs (26, 27).

The nonsynonymous rs3736228 polymorphism has been the most widely studied SNP in candidate gene studies (25, 28) and was identified as a quantitative trait locus in the Rotterdam cohort GWAS. It showed a stronger association with spine BMD than with femoral neck BMD (26). In a meta-analysis including ten eligible studies with 16 705 individuals, Tran *et al.* (25)

Figure 3 Association of *LRP5* polymorphisms with osteoporotic vertebral fractures (A), femoral neck projected area (B), and height (C). Nominal *P* values under an additive age-adjusted model.

Table 4 Association of *LRP5* polymorphisms with hip fractures. Odds ratio (OR), limits of the 95% confidence interval (L95 and U95), and *P* values for additive models in the unadjusted and age-adjusted analyses.

SNP	Allele	Unadjusted analysis				Age-adjusted analysis			
		OR	L95	U95	<i>P</i>	OR	L95	U95	<i>P</i>
rs4988330	T	0.84	0.59	1.20	0.36	1.02	0.65	1.59	0.91
rs7116604	A	0.90	0.67	1.19	0.47	1.15	0.80	1.64	0.43
rs312014	C	1.01	0.84	1.22	0.86	0.88	0.70	1.11	0.30
rs4988331	T	0.59	0.41	0.85	0.005	0.71	0.46	1.10	0.13
rs4988300	G	1.25	1.04	1.50	0.017	1.12	0.89	1.40	0.32
rs3781600	C	0.98	0.73	1.31	0.91	1.14	0.79	1.64	0.46
rs312024	A	1.16	0.95	1.41	0.13	0.95	0.74	1.21	0.69
rs314779	G	0.90	0.74	1.10	0.31	0.90	0.70	1.14	0.40
rs606989	T	0.89	0.65	1.22	0.48	1.10	0.74	1.61	0.62
rs314756	G	0.87	0.60	1.26	0.49	0.81	0.52	1.27	0.36
rs3781596	C	0.74	0.56	0.97	0.033	0.93	0.66	1.31	0.70
rs643981	T	0.85	0.71	1.02	0.09	0.87	0.69	1.09	0.24
rs312786	T	0.93	0.76	1.14	0.52	0.83	0.65	1.07	0.16
rs312788	G	0.84	0.70	1.02	0.08	0.86	0.69	1.08	0.19
rs160607	A	0.81	0.67	0.97	0.025	0.83	0.67	1.04	0.12
rs11826287	C	0.96	0.76	1.22	0.78	0.90	0.67	1.19	0.47
rs671191	C	0.86	0.71	1.03	0.11	0.91	0.73	1.14	0.43
rs4930573	G	1.00	0.81	1.22	0.99	0.88	0.69	1.13	0.34
rs587397	G	0.84	0.60	1.17	0.31	0.81	0.53	1.22	0.31
rs4988321	A	1.10	0.78	1.56	0.55	1.12	0.73	1.71	0.58
rs2306862	T	1.01	0.80	1.28	0.88	0.93	0.69	1.24	0.62
rs923346	C	1.02	0.80	1.29	0.86	0.94	0.70	1.25	0.68
rs1784235	C	0.97	0.79	1.20	0.84	0.89	0.68	1.15	0.37
rs556442	G	0.94	0.77	1.14	0.54	0.99	0.77	1.26	0.95
rs12417014	T	0.88	0.64	1.21	0.44	0.99	0.66	1.47	0.97
rs3781579	G	0.97	0.76	1.25	0.86	0.96	0.70	1.31	0.81
rs632605	A	0.80	0.56	1.16	0.24	1.03	0.65	1.62	0.89

Statistically significant values appear in boldface.

estimated that the difference in femoral neck BMD across rs3736288 genotypes was 0.011 g/cm², roughly equivalent to 0.1 s.d. Our study was not powered to detect such a small difference. The *LRP5* polymorphism was also associated with fractures in the GWAS and in a large multicenter study (29). In this study, we confirmed the trend for association with vertebral fractures, but we were not able to confirm the association with BMD. Several factors may explain the differences between studies, including age and menopausal status of subjects. In fact, the association with fractures, but not with BMD, might suggest an effect of *LRP5* alleles on other factors influencing bone strength, such as bone tissue quality or bone geometry. In this study, some *LRP5* polymorphisms were associated with body height and femoral neck size. This is in line with previously published results (30), and suggests that *LRP5* may influence skeletal development and growth, and consequently the peak bone mass attained in early adulthood, as also suggested by studies showing an association of *LRP5* polymorphisms with BMD in children and young adults (30–33). However, *LRP5* SNPs associated with fractures did not coincide with those associated with height or femoral neck projected area. Therefore, further studies are needed to clarify the mechanism explaining the association of *LRP5* variants with fractures.

LRP5 and *LRP6* are known to bind Wnt ligands, but their relative importance in bone tissue is unclear. Although several mutations of the *LRP5* gene have been associated with abnormal human bone phenotypes (20, 21, 23, 34, 35), only a pedigree with an *LRP6* mutation causing metabolic syndrome, coronary heart disease, and osteoporosis has been reported (36). Studies with knockout mice suggest that both *LRP5* and *LRP6* are needed for the normal skeletal homeostasis (3, 4). In this study, we showed that *LRP5* and *LRP6* are expressed in similar amounts in human bone. However, unlike *LRP5* polymorphisms, the association of genetic variants of *LRP6* with bone mass has been rarely studied, and controversial results have been reported. van Meurs *et al.* (6) first published that the nonsynonymous rs2302685 polymorphism (Ile1062Val) of the *LRP6* gene was associated with fragility fractures in men of the Rotterdam cohort. However, the results were not confirmed in a multicenter study (29) and no evidence for association with SNPs in the *LRP6* region was found in a meta-analysis of data directly obtained or imputed from GWAS results (37). However, Sims *et al.* (5) reported an association of genetic variants of *LRP6*, and specifically rs11054704, with BMD in postmenopausal women. Trying to clarify the possible influence of *LRP6* variants on bone mass, we performed a gene-wide analysis including tagging *LRP6* SNPs in a defined

population of postmenopausal women. There is no doubt that exploring the association of several SNPs with a phenotype inflate type I error (i.e. the possibility of false-positive associations). However, there is no general consensus about the best way to control it without compromising study power, particularly in hypothesis-driven candidate gene studies with several SNPs in linkage disequilibrium. In this study, we have used the method proposed by Nyholt (19), which takes into consideration the linkage between the genotyped loci. The replication in the independent cohorts may be the best way to confirm that the results are not just a chance finding. In this study, we have found an association of *LRP6* SNPs with BMD, with some *P* values below the multiple-test-adjusted threshold of significance. Furthermore, in the replication cohort we found a consistent association of two *LRP6* polymorphisms with BMD. Thus, our results support the hypothesis that allelic variants of *LRP6* are associated with BMD in postmenopausal women.

The nonsynonymous polymorphism rs2302865 is located in exon 14 of the *LRP6* gene and causes an isoleucine/valine change. The rs11054704 polymorphism is located in intron 15, just 2.1 kb downstream of rs2302865, and both belong to the same haplotypic block. The molecular mechanisms involved in the association of these SNPs with BMD remain to be elucidated. Nevertheless, according to the Fast SNP bioinformatic tool (<http://fastsnp.ibms.sinica.edu.tw>), the region including rs11054704 may act as an intronic enhancer and there may be allelic differences in the binding affinity for some transcription factors (CEBP/β, CdxA). On the other hand, different rs2302865 alleles not only induce an amino acid change, which may impair the activity of *LRP6*, but they may also have splicing regulatory consequences. Therefore, considered together, these results strongly suggest that these polymorphisms, or other linked variants located in the same region of the *LRP6* gene, are indeed associated with individual differences in BMD. Our data suggest that in women with the least frequent homozygous genotype BMD is 0.5 s.d. lower than in those with the most frequent genotype. Such a difference is likely to have an important influence at the individual level, but it may be less important at the population level, because the risk genotype is present in only 2–3% of women. The explanation for the negative results in other studies is unclear (7, 29), but it might be related to differences in the populations studied or to cohort heterogeneity.

This study has several limitations. We estimated that the number of subjects included in Cantabria cohort resulted in 89% power to detect a genetic effect explaining 1% of the BMD variance. However, the sample size limited the statistical power to detect smaller effects, particularly in the replication cohort, which was relatively small and without enough numbers of fractures for replication (only clinical vertebral fractures

were recorded because X-rays were not routinely obtained). We were not able to demonstrate a parallel association of *LRP6* polymorphisms with fractures, which may be related to the small number of homozygotes for the risk allele and the moderate size of our fracture subgroup, which limited the power of the study when the minor allele frequencies were small. We do not have anthropometric data of patients with hip fractures. Therefore, we could not include some potentially important factors, such as body weight, as covariates.

In summary, our data is in line with previously published studies showing an association of *LRP5* polymorphisms with osteoporotic fractures and strongly suggest that some genetic variants of *LRP6* are associated with BMD in postmenopausal women, pointing toward both Wnt co-receptors as osteoporosis candidate genes.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study was supported by grants from Instituto de Salud Carlos III-Fondo de Investigaciones Sanitarias (PI 06/0034, 08/0183, PS09/00184, and PS09/01687).

References

- 1 Jeong YH, Sekiya M, Hirata M, Ye M, Yamagishi A, Lee SM, Kang MJ, Hosoda A, Fukumura T, Kim DH & Saeki S. The low-density lipoprotein receptor-related protein 10 is a negative regulator of the canonical Wnt/beta-catenin signaling pathway. *Biochemical and Biophysical Research Communications* 2010 **392** 495–499. (doi:10.1016/j.bbrc.2010.01.049)
- 2 Yadav VK, Ryu JH, Suda N, Tanaka KE, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P & Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. *Cell* 2008 **135** 825–837. (doi:10.1016/j.cell.2008.09.059)
- 3 Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML & Williams BO. Decreased BMD and limb deformities in mice carrying mutations in both *Lrp5* and *Lrp6*. *Journal of Bone and Mineral Research* 2004 **19** 2033–2040. (doi:10.1359/jbmr.040907)
- 4 Zylstra CR, Wan C, VanKoeveering KK, Sanders AK, Lindvall C, Clemens TL & Williams BO. Gene targeting approaches in mice: assessing the roles of *LRP5* and *LRP6* in osteoblasts. *Journal of Musculoskeletal & Neuronal Interactions* 2008 **8** 291–293.
- 5 Sims AM, Shephard N, Carter K, Doan T, Dowling A, Duncan EL, Eisman J, Jones G, Nicholson G, Prince R, Seeman E, Thomas G, Wass JA & Brown MA. Genetic analyses in a sample of individuals with high or low bone density demonstrates association with multiple Wnt pathway genes. *Journal of Bone and Mineral Research* 2008 **23** 499–506. (doi:10.1359/jbmr.071113)
- 6 van Meurs JB, Rivadeneira F, Jhamai M, Hagens W, Hofman A, van Leeuwen JP, Pols HA & Uitterlinden AG. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. *Journal of Bone and Mineral Research* 2006 **21** 141–150. (doi:10.1359/jbmr.050904)

- 7 Mencej-Bedrac S, Prezeli J, Kocjan T, Komadina R & Marc J. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population. *Calcified Tissue International* 2009 **85** 501–506. (doi:10.1007/s00223-009-9306-y)
- 8 Yerges LM, Klei L, Cauley JA, Roeder K, Kammerer CM, Ensrud KE, Nestlerode CS, Lewis C, Lang TF, Barrett-Connor E, Moffett SP, Hoffman AR, Ferrell RE, Orwoll ES & Zmuda JM. Candidate gene analysis of femoral neck trabecular and cortical volumetric bone mineral density in older men. *Journal of Bone and Mineral Research* 2010 **25** 330–338. (doi:10.1359/jbmr.090729)
- 9 Olmos JM, Hernandez JL, Martinez J, Pariente E, Llorca J & Gonzalez-Macias J. Bone turnover markers in Spanish adult men: the Camargo Cohort Study. *Clinica Chimica Acta* 2010 **411** 19–20. (doi:10.1016/j.cca.2010.06.010)
- 10 Lu Y, Fuerst T, Hui S & Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. *Osteoporosis International* 2001 **12** 438–444. (doi:10.1007/s001980170087)
- 11 Barrett JC, Fry B, Maller J & Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005 **21** 263–265. (doi:10.1093/bioinformatics/bth457)
- 12 Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F, Schymkowitz J & Dopazo J. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. *Nucleic Acids Research* 2006 **34** W621–W625. (doi:10.1093/nar/gkl071)
- 13 Reumers J, Conde L, Medina I, Maurer-Stroh S, Van Durme J, Dopazo J, Rousseau F & Schymkowitz J. Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeff and PupaSuite databases. *Nucleic Acids Research* 2008 **36** D825–D829. (doi:10.1093/nar/gkm979)
- 14 Livak KJ & Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. *Methods* 2001 **25** 402–408. (doi:10.1006/meth.2001.1262)
- 15 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ & Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics* 2007 **81** 559–575. (doi:10.1086/519795)
- 16 Pritchard JK, Stephens M & Donnelly P. Inference of population structure using multilocus genotype data. *Genetics* 2000 **155** 945–959.
- 17 Petitti DB. *Meta-analysis, Decision Analysis and Cost-effectiveness Analysis. Methods for Quantitative Synthesis in Medicine* New York: Oxford University Press, 2000.
- 18 Bax L, Yu LM, Ikeda N, Tsuruta H & Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Medical Research Methodology* 2006 **6** 50. (doi:10.1186/1471-2288-6-50)
- 19 Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *American Journal of Human Genetics* 2004 **74** 765–769. (doi:10.1086/383251)
- 20 Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Bencheikroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogue X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR & Johnson ML. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. *American Journal of Human Genetics* 2002 **70** 11–19. (doi:10.1086/338450)
- 21 Balemans W & Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. *Endocrinology* 2007 **148** 2622–2629. (doi:10.1210/en.2006-1352)
- 22 Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakis G, Apte S, Adkins WN, Allgrove J, Arslan-Kirschner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, de Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, Lacombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR & Warman ML. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell* 2001 **107** 513–523. (doi:10.1016/S0092-8674(01)00571-2)
- 23 Narumi S, Numakura C, Shihara T, Seiwa C, Nozaki Y, Yamagata T, Momoi MY, Watanabe Y, Yoshino M, Matsushita T, Nishi E, Kawame H, Akahane T, Nishimura G, Emi M & Hasegawa T. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. *American Journal of Medical Genetics* 2010 **152A** 133–140. (doi:10.1002/ajmg.a.33177)
- 24 Agueda L, Bustamante M, Jurado S, Garcia-Giralto N, Ciria M, Salo G, Carreras R, Nogue X, Mellibovsky L, Diez-Perez A, Grinberg D & Balcells S. A haplotype-based analysis of the LRP5 gene in relation to osteoporosis phenotypes in Spanish postmenopausal women. *Journal of Bone and Mineral Research* 2008 **23** 1954–1963. (doi:10.1359/jbmr.080806)
- 25 Tran BN, Nguyen ND, Eisman JA & Nguyen TV. Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. *BMC Medical Genetics* 2008 **9** 55. (doi:10.1186/1471-2350-9-55)
- 26 Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR, Valdes AM, Arp P, Whittaker P, Verlaan DJ, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB, Hofman A, Pols HA, Hart D, Zhai G, Kato BS, Mullin BH, Zhang F, Deloukas P, Uitterlinden AG & Spector TD. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. *Lancet* 2008 **371** 1505–1512. (doi:10.1016/S0140-6736(08)60599-1)
- 27 Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DE, Walters SG, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U & Stefansson K. Multiple genetic loci for bone mineral density and fractures. *New England Journal of Medicine* 2008 **358** 2355–2365. (doi:10.1056/NEJMoa0801197)
- 28 Lee YH, Woo JH, Choi SJ, Ji JD & Song GG. Association between the A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene and bone mineral density: a meta-analysis. *Rheumatology International* 2009 **29** 539–544. (doi:10.1007/s00296-008-0745-y)
- 29 van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellstrom D, Mosekilde L, Nogue X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP & Uitterlinden AG. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. *Journal of the American Medical Association* 2008 **299** 1277–1290. (doi:10.1001/jama.299.11.1277)
- 30 Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermizakis ET, Rizzoli R & Antonarakis SE. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. *American Journal of Human Genetics* 2004 **74** 866–875. (doi:10.1086/420771)

- 31 Giroux S, Elfassihi L, Cardinal G, Laflamme N & Rousseau F. LRP5 coding polymorphisms influence the variation of peak bone mass in a normal population of French-Canadian women. *Bone* 2007 **40** 1299–1307. (doi:10.1016/j.bone.2007.01.004)
- 32 Brixen K, Beckers S, Peeters A, PETERS E, Balemans W, Nielsen TL, Wraae K, Bathum L, Brasen C, Hagen C, Andersen M, Van Hul W & Abrahamsen B. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with peak bone mass in non-sedentary men: results from the Odense androgen study. *Calcified Tissue International* 2007 **81** 421–429. (doi:10.1007/s00223-007-9088-z)
- 33 Koay MA, Tobias JH, Leary SD, Steer CD, Vilarino-Guell C & Brown MA. The effect of LRP5 polymorphisms on bone mineral density is apparent in childhood. *Calcified Tissue International* 2007 **81** 1–9. (doi:10.1007/s00223-007-9024-2)
- 34 Chung BD, Kayserili H, Ai M, Freudenberg J, Uzumcu A, Uyguner O, Bartels CF, Honing S, Ramirez A, Hanisch FG, Nurnberg G, Nurnberg P, Warman ML, Wollnik B, Kubisch C & Netzer C. A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. *Human Mutation* 2009 **30** 641–648. (doi:10.1002/humu.20916)
- 35 Streeten EA, McBride D, Puffenberger E, Hoffman ME, Pollin TI, Donnelly P, Sack P & Morton H. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. *Bone* 2008 **43** 584–590. (doi:10.1016/j.bone.2008.04.020)
- 36 Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D & Lifton RP. LRP6 mutation in a family with early coronary disease and metabolic risk factors. *Science* 2007 **315** 1278–1282. (doi:10.1126/science.1136370)
- 37 Richards JB, Kavvoura FK, Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, Van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP & Spector TD. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. *Annals of Internal Medicine* 2009 **151** 528–537.

Received 2 October 2010

Accepted 6 October 2010